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Abstract
Recombinant subunit vaccines are an efficient strategy to meet 
the demands of a possible influenza pandemic, because of rapid and 
scalable production.  However, vaccines made from recombinant 
Hemagglutinin (HA) subunit protein are often of low potency, requiring repeated boosting to generate a sustained immune 
response.  Previously, we demonstrated  improved immunogenicity of a plant-made H1 Hemagglutinin (HA) vaccine by chemical conjugation to the surface of the Tobacco Mosaic Virus (TMV) which is non infectious in mammals.  Antigen coated TMV is taken up by mammalian dendritic cells and is a highly effective antigen 
carrier for subunit protein vaccines.  In this work, we tested the effectiveness of a TMV-H5 HA conjugate vaccine.  We compared the 
TMV-H5 immunogenicity in mice, with and without an oil-in water 
squalene adjuvant, to H5N1 virus or HA protein alone, as measured by anti-H5 IgG titers and Hemagglutination Inhibition (HAI).  We then 
evaluated the efficacy of the TMV-H5 vaccine by lethal H5N1 virus challenge in mice.  Our results show that a single dose of the TMV-H5 
conjugate vaccine is sufficient to generate 40% survival, similar to H5 
protein given with adjuvant, or 100% survival after vaccination with 
adjuvant, similar to H5N1 virus vaccination.  
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Introduction
Vaccination against influenza A infection has undoubtedly 
saved millions of lives, but zoonotic influenza represents a 
continuous source of potentially new infectious virus strains, 
either by mutation to promote human infections, or by genetic shift through reassortment with a human seasonal influenza. 
Since 1997, H5N1 has emerged as a potentially pandemic 
virus from human contact with infectious birds [1], with an 
alarmingly high fatality rate of ~53% [2].  Unfortunately the 
H5N1 virus continues to generate a high rate of mutation, and 
many new clades of virus [3-5].  This is of special concern, because 1) the strain banked against a possible pandemic may 
not be immunologically relevant [6], 2) the poor efficacy of the 
current vaccine will require two immunizations (with adjuvant) to achieve homologous or heterologous immunity in vaccinated 
individuals [7, 8], or 3) that it will take months to scale up 
embryonated egg-based vaccine production, which may be too 
slow to facilitate mass immunization.  
Significant progress has been made to rapidly produce 
H5N1 vaccines by expression of the Hemagglutinin (HA) protein as the vaccine agent.  HA protein is the main stimulus of virus 
neutralization, and can be made independently of the whole 
virus.  Production is much safer, simpler and faster [9], and H5 HA 
immunization generates protective immunity in mice [10], ferrets 
[11, 12] and in humans [13-15].  But, H5 HA protein is weakly 
immunogenic, and requires boosting and/or adjuvant use for 
inducing effective immunity, so immune potency is still an issue. 
We have optimized HA formulation by chemically associating H5 
HA protein to the surface of, Tobacco Mosaic Virus (TMV), a non-
infectious plant virus.  TMV is an attractive virus carrier, because 
it has the optimal size to promote immune cell uptake [16, 17], can be made at Kg scale in planta with a minimum of processing 
steps, and is not a mammalian pathogen [18].  We have developed a TMV coat protein variant that expresses a surface exposed 
lysine [19] that allows for high density association of HA protein 
to the virus surface, using a one step conjugation chemistry [20]. 
In this study, we have greatly improved the low immunogenicity 
of H5 HA subunit vaccination by TMV-H5 conjugation, with 
equivalent immune activation potency as an MF-59-like squalene adjuvant.  This could be an important advance in development of dose-sparing protective HA vaccines that are based on subunit antigen delivery by virus co-formulation.
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Materials and methods
Conjugation and Vaccine preparation
Chemical conjugation of an H5 HA1 Fc fusion protein (10003-
V06H1, Sino Biological Inc.,) to the surface of lysine modified TMV 
virus [19], was done as previously described [20].  Conjugation reactions were considered complete when no free HA protein 
was visible by SDS-PAGE.  After conjugation, reactive agents 
were removed by overnight dialysis against PBS in Slide-a-Lyzer 
cartridge (Thermo-Scientific), and the protein quantity was 
determined by the Bicinchoninic Acid Assay (BCA;BioRad), and 
HA content was quantified by Enzyme Linked Immunosorbent 
Assay (ELISA), to normalize the vaccine dose. 
Vaccination and immune response evaluation in mice
BALB/c mice (Charles River, CA) were housed at Touro 
University according to guidelines established in the Care and 
Use of Animals and according to IACUC approved protocols. 
Mice were given a 100 – 200 µl subcutaneous (s.c.) injection 
of 7.5 μg HA protein (unconjugated), or the equivalent HA as a 
15 μg conjugate, with or without a squalene based oil-in-water 
emulsion adjuvant AddaVax™ (1:1 ratio; InvivoGen).  Inactivated 
H5N1 virus was used as a positive control, and pre-immune serum was used to determine baseline sera titers.  Vaccines were 
administered on day one and day 30, and sera was collected by 
tail vein bleed on days 14 and 28 days post vaccine 1 (pV1) or day 
44, 14 days post vaccine 2 (pV2) for ELISA analysis.  
ELISA was used to determine serum IgG titers as previously 
described [21].  Anti-H5 titers reported in ng/ml were determined 
from a standard curve generated by a 3-fold serial dilution of a 10 
ng/ml mouse anti-HA monoclonal antibody (DPJY01, BEI #NR-
19869).  Hemagglutinin Inhibition (HAI) titers of the sera were 
then determined by the standard microtitration method [22], 
with serial 2-fold dilution of serum mixed with 0.5% turkey Red 
Blood Cells (RBCs; Innovative Research, Inc.) in sterile phosphate 
buffered saline (PBS;Gibco).
H5N1 virus challenge
H5N1 virus challenge studies were conducted under animal 
Bio-safety level 3 (ABSL3) conditions and according to St. Jude Children’s Research Hospital approved institutional procedures 
and protocols.  Ten week old BALB/c mice were vaccinated once, 
using 15 µg H5 protein equivalent, or two times 14 days apart 
with 7.5 µg H5 protein equivalent, with or without squalene 
based adjuvant.  At day 26, serum was collected for ELISA and 
HAI analysis, and on day 28, mice were challenged intranasally 
with 10xLD50 of highly pathogenic avian A/Vietnam/1203/04, 
diluted in 50 µL of PBS, as previously described [23].  Mice were 
monitored daily for >25% weight loss, neurologic signs, or motor 
dysfunction, and were euthanized according to IACUC approved procedures.
Results and discussion 
TMV-H5 HA conjugation and pilot immunization
As shown in Figure 1, we used EDC/NHS (1-Ethyl-3-(3-
dimethylaminopropyl) carbodiimide/N-hydroxysuccinimide) 
conjugation of H5 HA (H5 HA1-Fc protein; Sino Biological Inc.,) 
to a lysine modified TMV as previously described [20].  After 30 
minutes, both TMV (triangle) and HA (circle) are reduced, and a high molecular weight aggregate (TMV-H5) accumulates in 
the gel above 250 kDa, and in the stack after 8-16% SDS-PAGE separation (arrow).  A TMV dimer and tetramer are also visible (asterisks). 
To assess immune response titers, 7.5 µg of HA equivalent 
protein as TMV-H5 conjugate was used to immunize mice (n=3), 
with or without a squalene based oil-in-water adjuvant (Sq; 
InvivoGen).  Inactivated H5N1 virus was also used as a positive 
control, and H5 protein given +/-Sq was used to control for HA immune reactivity without TMV.  Mice were tested for anti-HA 
IgG 14 and 28 days after a single dose, and at day 44, 14 days 
after a boost on day 30.  As shown in Figure 2A, all immunized 
mice had measureable anti-H5 specific IgG titers after a single 
dose of TMV-H5, when compared to an anti-H5 monoclonal 
antibody standard (DPJY01, BEI #NR-19869).  Only TMV-H5 with 
Sq had significantly better immune titers (* p < 0.05) than any 
of the other vaccine groups, suggesting synergy in H5 immune 
potentiation between TMV and adjuvant.  Notably, TMV-H5 had statistically similar immune titers compared to H5 HA 
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Figure 1: Preparation of the TMV-H5 conjugate vaccine.
A 1:1 mass ratio of TMV-lysine (T: filled triangle) and H5 HA1 protein 
(H5: filled circle; Sino Biologicals #10003-V06H1; homologous to A/
Vietnam/1203/2004) were reacted in the presence of EDC/NHS for 
0, 30, 60 or 90 minutes, and then stopped with the addition of 10mM 
methylamine.  Reactions were dialyzed against PBS, and then 3 µg 
protein was separated by an 8-16% gradient SDS-PAGE (BioRad), compared to Precision Plus molecular weight standard (BioRad). High molecular weight conjugate product (arrow) and TMV dimers/
mulitmers (asterisks) are seen after 30 minutes, and are not increased by further incubation time.
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Figure 2: TMV-H5 vaccine pilot study; IgG titers and HAI.  Mice were immunized one time with 7.5 µg of H5 equivalent protein, or H5N1 virus as 
a control.  At 14 (b1) or 28 (b2) days post vaccine 1 (A/B), serum was collected, and tested for total IgG by ELISA on plates coated with 5ug/ml bacu-
lovirus expressed H5  protein (BEI # NR-10510).  Serum responses were quantified against  a standard curve of 10ng/ml anti-H5 IgG (DPJY01, BEI 
#NR-19869), and  differences in response are indicated (significant *:p≤0.05;NS:not significantly different).  One additional dose was administered at 
day 30, and bleed 3 serum responses were measured at day 44 by the same method (C). Relevant H5N1 virus (A/Vietnam/1203/2004) was titered for turkey RBC agglutination (D).  Virus at 4 fold greater than the minimum agglutinating titer was then pretreated with serial dilutions of RDE-treated 
serum from study sera.  After 1 hour, 0.05% turkey red blood cells were added, and HAI titer was measured as the inverse of  the minimum dilution blocking the formation of RBC agglutination (RBC buttons).  TMV vaccination gave titers equivalent to pre-immune sera (not shown).
protein given with squalene (NS; not significantly different), indicating that TMV provides adjuvant activity equivalent to 
that of squalene emulsions [20]. After two weeks (Figure 2B), 
the immune response to TMV-H5 Sq nearly doubled (mean 6.3 
vs 11.1), suggesting that TMV-HA vaccines may also provide a 
depot effect.  Two weeks after a second immunization (Figure 
2C), TMV-H5 Sq boosted mice had a log increase in IgG titer 
(mean 11.1 vs 140.0) which was significantly better than other 
vaccine groups (p < 0.001), and all other immune responses were 
statistically similar to each other (NS).  
Although IgG titers were low for both H5N1 virus and H5 HA 
Sq after two immunizations, significant HAI titers (> 40) were measured for all vaccine groups except HA protein given without 
adjuvant (* p < 0.05; Figure 2D), indicating both quantitative and qualitative boosting of TMV-HA conjugate vaccines.  
Immunization and protection from H5N1 viral 
challenge  
As shown in Figure 3A, mice were immunized following a 
similar strategy in the pilot study.  Mice (n=10) were vaccinated 
with either one dose (15 µg total HA protein) on day 1, or two 
doses on days 1 and 14 (7.5 µg each dose, 15 µg total HA protein), with or without oil-in-water squalene (Sq) adjuvant as indicated. HA only was not tested in this study due to lack of IgG and HAI 
responses in the pilot study.  Sera were collected on day 28, and 
mice were challenged on day 30 by intranasal administration 
of 10xLD50 of A/Vietnam/1203/04.  Mice were monitored for 
symptoms of infection (weight loss, neurological or behavioral 
changes), and euthanized according to IACUC protocols.  As 
shown in Figure 3B, IgG immune response titers were slightly 
different than the pilot, especially in regards to inactivated 
H5N1 virus responses, which were much higher than in the pilot, possibly due to differences in preparations and estimates 
of HA content.  Another difference, was the low IgG induced by 
TMV-HA, after either one or two vaccines.  However, after one 
dose TMV-HA+Sq induced significantly higher IgG titers than 
HA+Sq (p < 0.05) and was not different than inactivated virus 
immunization.  After two doses, TMV-HA+Sq, HA+Sq and H5N1 
virus immunization induced similar levels of IgG.  In contrast, HAI 
titers (Figure 3C) for TMV-HA were significantly better after two 
doses than HA+Sq, with or without squalene adjuvant addition. 
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Figure 3: TMV-H5 challenge study; IgG titers and HAI. A. Mice were immunized two times,14 days apart, with 7.5 µg of H5 equivalent protein, or 
one time with 15 µg of equivalent H5 protein, using H5N1 virus or PBS as controls.  B. At 28, serum was collected, and tested for total IgG by ELISA 
on plates coated with 5 µg/ml baculovirus expressed H5  protein (BEI # NR-10510).  Serum responses were quantified against  a standard curve of 
10ng/ml anti-H5 IgG (DPJY01, BEI #NR-19869).  C. The minimum agglutinating titer was determined with serial dilutions of RDE-treated serum (as 
in Figure 2). 
Figure 4: TMV-H5 challenge study;  weight loss and survival.  Mice were immunized two times,14 days apart, with 7.5 µg of H5 equivalent pro-
tein, or one time with 15 µg of equivalent H5 protein, using H5N1 virus or PBS as controls.  At day 30, mice were challenged by intranasal delivery 
of 10xLD50 H5N1 virus.  Mice were weighed every other day, and euthanized if less than 80% of starting weight, or had signs of neurological or be-havioral distress.  A/C. Weights were plotted as the average +/- the standard error of measurement.  B/D. Survival was calculated by Kaplan-Meier analysis. 
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After a single dose, HAI titer was also significantly better in the 
TMV-HA+Sq than HA+Sq vaccine group (p < 0.05), but was not 
above background (< 40) in the TMV-HA group.       
At day 30, mice were challenged with a lethal dose of A/
Vietnam/1203/04, and monitored for weight changes and 
survival.  After one immunization, TMV-HA+Sq generated 
equivalent protection to inactivated H5N1 virus vaccination 
(100% of mice) both in terms of weight loss (Figure 4A) and 
survival (Figure 4B).  Surprisingly, despite low IgG and low HAI 
for TMV-HA after one dose (no adjuvant), we measured 40% 
survival, equivalent to HA+Sq (Figure 4B), indicating that TMV provides immune activation activity similar or equal to that of a 
squalene-based MF-59-like adjuvant.  After  two immunizations, 
all vaccine groups had statistically similar survival (90-100%; 
p > 0.9), irrespective of adjuvant use, and compared to the PBS 
control (p < 0.01).  Ongoing studies to further improve TMV-HA formulations 
include intranasal administration, to improve mucosal immunity, 
multivalent combinations of various TMV-HAs, and additional adjuvant co-formulations.  Preliminary data suggest higher mean titers of anti-H5 IgG are achieved with TMV-H5 intranasal 
dosing, but HAI, microneutralization analysis, cross protection, 
and challenge studies will be needed to confirm relevance to 
protection, similar to other studies using HA virus-like particles 
[24], nanoparticles [25] or virus vaccines [26]. 
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